AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
The CHMP recommends approval of AstraZenecas (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on…
69,424$
-0,18%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Total Voting Rights
1 July 2024 15:00 BST
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
…
Global Food Allergy Treatment Market Size To Worth USD 13.76 Billion By 2033 | CAGR of 9.27%
The Global Food Allergy Treatment Market Size was Valued at USD 5.67 Billion in 2023 and the Worldwide Food Allergy…
Pharma Stock Roundup: FDAs CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
FDA rejects Merck (MRK) and AbbVies (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.…
AstraZenecas (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZenecas (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery…
Oncology Stocks: 8 Biggest NASDAQ Companies in 2024
The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…
AstraZenecas Oncology Success: Fueling Future Growth
…
BenevolentAI and AstraZeneca collaborate on new lupus target
…
BenevolentAI says second target identified by AstraZeneca collaboration
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the formers artificial...…